- Home
- SKE vs IMCR Comparison
SKE vs IMCR Comparison
Compare SKE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKE | IMCR |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SKE | IMCR |
|---|---|---|
| Price | $25.46 | $36.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | ★ 839.6K | 276.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | N/A | $10.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $8.53 | $23.15 |
| 52 Week High | $26.05 | $40.72 |
Technical Indicators
Market Signals| Indicator | SKE | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 71.00 | 49.55 |
| Support Level | $23.97 | $35.41 |
| Resistance Level | $24.98 | $37.25 |
| Average True Range (ATR) | 1.14 | 1.58 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 85.34 | 26.41 |
Price Performance
Historical ComparisonAbout SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.